FDA grants orphan drug designation for neuroblastoma vaccine

The U.S. Food and Drug Administration granted orphan drug designation for a neuroblastoma vaccine from MabVax Therapeutics, providing development incentive with market exclusivity of the novel treatment for children with this deadly childhood cancer.

Read the article:
FDA grants orphan drug designation for neuroblastoma vaccine

Share and Enjoy:
  • Print
  • Digg
  • StumbleUpon
  • Facebook
  • Yahoo! Buzz
  • Twitter
  • Google Bookmarks
  • Add to favorites
  • email
  • LinkedIn
  • RSS
  • Tumblr
Share